Operational Oversight or Compliance Theater
If your governance model produces 12 pages of meeting minutes, but no clear decision, owner, or change in course, it is not operational oversight. It might be compliance theater.
As organizations implement ICH E6(R3), I worry that some will respond as our industry often does to change: add another meeting, expand the checklist, build another dashboard, and document every discussion in greater detail.
But R3 is not a mandate to create more evidence. It is an opportunity to strengthen clinical operations and delivery excellence by redesigning how we identify, discuss, and act on risks that affect participant safety, rights, data reliability, and study execution.
Too often, governance becomes performative:
Standing meetings attended out of habit rather than operational purpose.
Minutes that capture every discussion but not the decision.
Escalation logs full of issues with no accountable owner.
Metrics reviewed month after month without triggering intervention.
Sponsor–CRO discussions that reward polished reporting over early transparency.
Governance forums disconnected from the teams responsible for day-to-day study delivery.
These rituals can make an organization look controlled. They do not necessarily make it more operationally effective or improve the likelihood of delivering a trial well.
Meaningful R3-aligned governance is different. It is focused, proportionate, risk-driven, and designed to enable action.
A governance model that supports operational excellence should answer a few questions:
What decisions is this forum empowered to make?
Which risks require cross-functional action or escalation?
Who owns the action, by when, and with what authority?
What data will trigger intervention?
Are sponsor and CRO teams equipped and encouraged to surface bad news early?
How will this decision improve delivery for sites, patients, and the study team?
For biotech and emerging biopharma, this does not require an elaborate committee structure. Lean organizations can build delivery excellence into their operating model before unnecessary bureaucracy takes hold.
R3 gives us an opportunity to move beyond governance as a reporting mechanism. We should use it to make governance an engine for operational excellence, meaningful collaboration, and better clinical trial delivery.
If your governance process produces more reporting than decisions—or more meetings than meaningful action—you may be documenting risk rather than managing it. Let’s talk.
From inside the meeting, the difference is genuinely hard to see. An outside read on your governance and oversight model tends to be quicker.
